Showing 2501-2510 of 9131 results for "".
Dupixent Approved for Spontaneous Urticaria
https://practicaldermatology.com/videos/dermwire-tv/dupixent-approved-for-spontaneous-urticaria/35635/In this week's DermwireTV, the FDA approves the first new therapy for spontaneous urticaria in more than 10 years; a new study examines investigational oral Icotrokinra in adolescents with plaque psoriasis; and Practical Dermatology launches a new series addressing trends and innovations in the treaJournal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EDermWire TV Extra: Spironolactone on TikTok
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-extra-spironolactone-on-tiktok/33016/George Washington University clinical instructor of Dermatology Emily Murphy, MD, and medical student Savanna Vidal discuss their research regarding the quality and reliability of information on TikTok about spironolactone for acne treatment.Practical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 6
https://practicaldermatology.com/videos/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-6/32904/In the final installment of a six-part series, host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, recap the recommended protocol for treating generalized psoriasis treatment, starting from the initial diagnosis, as well as the safety of targetedPediatric, Acne, and AD Sessions: Dr. Eichenfield
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/pediatric-acne-and-ad-sessions-dr-eichenfield/32684/Lawrence Eichenfield, MD, discusses his presentations from Maui Derm 2025, which included "Pediatric Dermatology 2025," "Update 2025: Acne and Rosacea," and "Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2025." Highlights include the importance of recognizing severe and rapid"You've Just Been Served": Dr. Goldberg
https://practicaldermatology.com/programs/practical-dermatology/youve-just-been-served-dr-goldberg/32691/David Goldberg, MD, JD, discusses lessening the likelihood of lawsuits and winning lawsuits involving negligence, employees, and teledermatology, which he covered during his session, "You've Just Been Served," at Maui Derm 2025.Epidermal Inclusion Cysts: Dr. Goldman
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/epidermal-inclusion-cysts-dr-goldman/32687/Mitchel Goldman, MD, who took part in the "Neuromodulator and Dermal Filler" panel at Maui Derm 2025, talks about a new treatment for epidermal inclusion cysts, involving sclerotherapy medication.Neuromodulators and Dermal Fillers: Dr. Gold
https://practicaldermatology.com/programs/practical-dermatology/neuromodulators-and-dermal-fillers-dr-gold/32694/Michael Gold, MD, talks about the new neurotoxins and applications, as well as fillers, that he covered during "Neuromodulators and Dermal Fillers: What's New, What's Coming and What Are We Doing That's New in 2025" at Maui Derm 2025.Combination Treatment: Dr. Shamban
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/combination-treatment-dr-shamban/32685/Ava Shamban, MD, talks about the combination treatments—such as energy-based devices, peels, and laser-assisted drug delivery—that she covered in "What's My Treatment? How to Combine Dermal Filler, Neuromodulators, Laser/Light/RF Devices/Microneedling and Cosmeceuticals Symposium" at Maui Derm 2025.Clinical Development of Emrosi for Rosacea
https://practicaldermatology.com/series/c-suite-chats/clinical-development-emrosi-rosacea/32379/Claude Maraoui, President and CEO of Journey Medical, discusses the clinical development program for Emrosi, which was recently approved by the FDA for inflammatory lesions of rosacea in adults.